On October 29, 2019 Caprion is reported its leadership role in a Pre-Conference Workshop at the upcoming AAPS PharmaSci 360 conference, San Antonio, Texas (Press release, Caprion, OCT 29, 2019, View Source [SID1234550002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The workshop initiated by Caprion’s team and led by Dr. Virginia Litwin, Vice-President of Flow Cytometry, will include pharmaceutical, biotech and regulatory leaders in biomarker research.

The workshop entitled "Best Practices for the Development and Fit-for-Purpose Validation of Biomarker Methods" will consist of presentations and break-out sessions, leading to consensus on the best practice for biomarker assay development and minimum validation requirements based on intended use. As a result of the workshop, a white paper will propose recommendations for the industry and regulatory agencies.

"Caprion’s involvement in this pre-conference workshop reflects its commitment to be an active player and a leader in defining the industry standards when it comes to the development of robust assay validation strategies", stated Dr. Lorella Di Donato, Senior Vice-President and Chief Operating Officer. "

Dr. Litwin is a frequent speaker, moderator, and panelist at pharmaceutical industry, scientific, and clinical conferences, and was recently recognized at the 2019 WRIB meeting for her outstanding contribution. She is the chair of the Document Development Committee for the new CLSI guidance document H62: The Validation of Assay Performed by Flow Cytometry, which will be open for public comment until November 18.